U.S. markets closed
  • S&P 500

    4,662.85
    +3.82 (+0.08%)
     
  • Dow 30

    35,911.81
    -201.79 (-0.56%)
     
  • Nasdaq

    14,893.75
    +86.95 (+0.59%)
     
  • Russell 2000

    2,162.46
    +3.02 (+0.14%)
     
  • Crude Oil

    84.36
    +0.54 (+0.64%)
     
  • Gold

    1,819.00
    +2.50 (+0.14%)
     
  • Silver

    23.02
    +0.11 (+0.47%)
     
  • EUR/USD

    1.1416
    0.0000 (-0.00%)
     
  • 10-Yr Bond

    1.7720
    +0.0610 (+3.57%)
     
  • GBP/USD

    1.3650
    -0.0030 (-0.22%)
     
  • USD/JPY

    114.5910
    +0.3910 (+0.34%)
     
  • BTC-USD

    41,957.09
    -1,152.23 (-2.67%)
     
  • CMC Crypto 200

    1,006.21
    -19.52 (-1.90%)
     
  • FTSE 100

    7,611.23
    +68.28 (+0.91%)
     
  • Nikkei 225

    28,333.52
    +209.24 (+0.74%)
     

Deargen Annonuces Patent Application for a TNBC Target Novel Drug Candidate Using AI

·4 min read
  • Using a self-developed AI platform, it takes only 10 weeks from the discovery of the anticancer drug targets to the discovery and synthesis of new compounds.

  • Proven capabilities for NCE compound discovery and design, and the establishment of a R&D center(iDear Center) to continuously develop patented substances.

SEOUL, South Korea, Dec. 22, 2021 /PRNewswire/ -- Deargen, a company specializing in the development of novel NCE drugs using artificial intelligence, announced on the 22rd that it had discovered and synthesized a new anticancer target compound using its own AI platform and had already applied for a patent for it.

Deargen has the technology to predict candidates for a novel drug without the 3D structure data of proteins. Deargen's technology, which uses amino acid sequence data rather than the structure information of proteins, possesses global-level differentiated artificial intelligence technology that enables the rapid development of novel drugs even for proteins whose 3D structure has not yet been identified.

An official from Deargen said : "The new compound for which we have applied for a patent this time is a first-in-class candidate, and we plan to develop a therapeutic agent targeting triple-negative breast cancer (TNBC). TNBC is an area where there are few novel drugs available and it is difficult to find innovative targets, so it is a disease with a high demand for new therapeutics…Deargen confirmed the efficacy of the new compound discovered through in-vitro experiments."

Also, the substance that Deargen discovered through this study is an NCE (New Chemical Entity). An NCE refers to a new chemically synthesized drug, which requires a great deal of time and money because it is difficult to develop such a drug that has not been previously approved by the FDA. However, it is within an area with high needs by many global pharmaceutical companies as it has the advantage of being able to receive market monopoly rights for 5 years in the U.S. and 10 years in Europe after product approval.

In particular, Deargen's achievements are significant in that it discovered the new compound in a shorter time than the existing novel drug discovery process through its collaboration of advanced AI and in-house experts for novel drug development. The target discovery and substance design process, which usually takes about 3 to 4 years in the existing traditional drug development process, was carried out in just 10 weeks, and it took merely 2 weeks for target discovery and 8 weeks for substance design and synthesis.

Currently, Deargen is establishing a large-scale R&D center (iDear Center). With this R&D center, the plan is to further shorten the period of the discovery of candidates by efficiently managing the time required for designing and synthesizing substances. The R&D center will be in charge of fast verification of substances by conducting the design and synthesis verification of substances under joint research with Deargen's internal pipeline, along with the production of high-quality data.

Daniel Bae, Chief Business Officer of Deargen said : "We plan to continuously derive new substances with patentability through our synthesis research center (iDear Center), which will be established in the first half of next year. We plan to not only build our own pipeline centered on anticancer drugs, but also to introduce various business models with our partners that go beyond the existing joint research contracts." He also said, "Deargen plans to establish its position among global AI drug developers as a company specializing in NCE drug development, from target discovery to compound design and synthesis."

About Deargen Inc.

Established in December 2016, Deargen (President: Kilsoo Kang) is an AI-based drug discovery and development company. In February 2020, the company released study results on predicting the development of COVID-19 treatments. Candidate compounds for treating COVID-19 predicted by Deargen include remdesivir, which was first approved as an emergency therapy. The company conducts research on and owns core AI technologies in-silico, such as 'prediction of bio-markers', 'selection of disease targets', and 'extraction of candidate substances for new drugs', utilizing techniques of meta analysis of genome big data and its unique AI technologies. Building on these outcomes, the company is developing new drugs in collaboration with multiple pharmaceutical companies and research institutions, demonstrating its outstanding technology capabilities as being named as top awardees at the ILSVRC, a world-prominent deep-learning competition, and Dream Challenge, an international AI-based new drug development competition.

Deargen Inc. Contact
Riaa Kim, riaa.kim@deargen.me

Cision
Cision

View original content:https://www.prnewswire.com/news-releases/deargen-annonuces-patent-application-for-a-tnbc-target-novel-drug-candidate-using-ai-301449794.html

SOURCE Deargen Inc.